"Analysis.group","Analysis.number","Analysis.name","Subgroup","Subgroup.number","Applicability","Study","Study.year","GIV.Mean","GIV.SE","Experimental.mean","Experimental.SD","Experimental.cases","Experimental.N","Control.mean","Control.SD","Control.cases","Control.N","O.E","Variance","Weight","Mean","CI.start","CI.end","Footnotes","Bias.arising.from.the.randomization.process.judgement","Bias.arising.from.the.randomization.process.support","Bias.due.to.deviations.from.intended.interventions.judgement","Bias.due.to.deviations.from.intended.interventions.support","Bias.due.to.missing.outcome.data.judgement","Bias.due.to.missing.outcome.data.support","Bias.in.measurement.of.the.outcome.judgement","Bias.in.measurement.of.the.outcome.support","Bias.in.selection.of.the.reported.result.judgement","Bias.in.selection.of.the.reported.result.support","Overall.bias.judgement","Overall.bias.support","review.url","review.doi","analysis_key","dataset_name","mismatch_type","direction_match","or_sig","rd_sig","log_or","rd","log_or_ci_lb","log_or_ci_ub","rd_ci_lb","rd_ci_ub","sparse_events","double_zero"
1,1,"Maternal sepsis","",NA,"SUBGROUP_AND_OVERALL","Oluwalana 2017",2017,NA,NA,NA,NA,4,414,NA,NA,5,415,NA,NA,1.540062,0.801932,0.216872,2.96532,NA,"Low risk","<ul><li>A double-blind, placebo-controlled randomized trial</li><li>Women in labour were randomized to receive either a single dose of 2 g of oral azithromycin or placebo (ratio 1:1)</li></ul>","","","","","","","","","","","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD016211/full","10.1002/14651858.CD016211","1::overall","CD016211_data","significance_only",TRUE,TRUE,FALSE,-0.43199609546437,-0.00406252903116841,-0.597180443098425,-0.266811747830315,-0.0096907068410749,0.00156564877873807,FALSE,FALSE
1,1,"Maternal sepsis","",NA,"SUBGROUP_AND_OVERALL","Roca 2023",2023,NA,NA,NA,NA,8,5802,NA,NA,13,5823,NA,NA,3.401132,0.617612,0.256181,1.488964,NA,"Low risk","<ul><li>Participants assignment to intervention (the 'intention-to-treat' effect)</li><li>Described as 'randomised, double-blind, placebo-controlled trial'&nbsp;</li><li>829 women randomly assigned (1:1)</li></ul>","","","","","","","","","","","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD016211/full","10.1002/14651858.CD016211","1::overall","CD016211_data","significance_only",TRUE,TRUE,FALSE,-0.43199609546437,-0.00406252903116841,-0.597180443098425,-0.266811747830315,-0.0096907068410749,0.00156564877873807,FALSE,FALSE
1,1,"Maternal sepsis","",NA,"SUBGROUP_AND_OVERALL","Subramaniam 2021",2021,NA,NA,NA,NA,8,506,NA,NA,5,250,NA,NA,2.149046,0.790514,0.261296,2.39159,NA,"Low risk","<p>The sequential randomization assignments were computer generated using permuted block sizes of 3, 6, and 9, and were stratified by site.&nbsp;</p>","","","","","","","","","","","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD016211/full","10.1002/14651858.CD016211","1::overall","CD016211_data","significance_only",TRUE,TRUE,FALSE,-0.43199609546437,-0.00406252903116841,-0.597180443098425,-0.266811747830315,-0.0096907068410749,0.00156564877873807,FALSE,FALSE
1,1,"Maternal sepsis","",NA,"SUBGROUP_AND_OVERALL","Tita 2023",2023,NA,NA,NA,NA,219,14558,NA,NA,339,14662,NA,NA,92.90976,0.650633,0.549814,0.769938,NA,"Low risk","<p>&nbsp;""Trial packs of azithromycin and identical placebo were numbered sequentially with the use of a compyter algorithm, which used a predetermined 1:1 randomization schedule for azithromycin and placebo, stratified according to site, and a permuted-block randomization with vaaried block sizes."" There was no clear differences between the intervention group and the control group.&nbsp;</p>","","","","","","","","","","","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD016211/full","10.1002/14651858.CD016211","1::overall","CD016211_data","significance_only",TRUE,TRUE,FALSE,-0.43199609546437,-0.00406252903116841,-0.597180443098425,-0.266811747830315,-0.0096907068410749,0.00156564877873807,FALSE,FALSE
1,2,"Maternal sepsis: subgroup analysis (polypharmacy vs monopharmacy)","Monopharmacy",2,"SUBGROUP_AND_OVERALL","Oluwalana 2017",2017,0,0,0,0,4,414,0,0,5,415,0,0,1.536657,0.801932,0.216872,2.96532,NA,"Low risk","<ul><li>A double-blind, placebo-controlled randomized trial</li><li>Women in labour were randomized to receive either a single dose of 2 g of oral azithromycin or placebo (ratio 1:1)</li></ul>","Low risk","<p>The active drug and the placebo looked identical. The study clinicians were blind to the treatment allocation. Probably ITT.</p>","Low risk","<p>Data was available for all participants randomized.</p>","Low risk","<p>Diagnoses were based on clinical judgement according to the study clinicians.&nbsp;</p>","Some concerns","<p>The present study and protocol have slightly different purposes.</p>","Some concerns","<p>The present study and protocol have slightly different purposes.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD016211/full","10.1002/14651858.CD016211","2::2","CD016211_data","significance_only",TRUE,TRUE,FALSE,-0.435092759704064,-0.00405764878410204,-0.601365776286879,-0.268819743121249,-0.00974038569362614,0.00162508812542207,FALSE,FALSE
1,2,"Maternal sepsis: subgroup analysis (polypharmacy vs monopharmacy)","Monopharmacy",2,"SUBGROUP_AND_OVERALL","Roca 2023",2023,0,0.448977792877733,0,0,8,5802,0,0,13,5823,0,0.201581058497361,3.393614,0.617612,0.256181,1.488964,NA,"Low risk","<ul><li>Participants assignment to intervention (the 'intention-to-treat' effect)</li><li>Described as 'randomised, double-blind, placebo-controlled trial'&nbsp;</li><li>829 women randomly assigned (1:1)</li></ul>","Low risk","<p>&nbsp;""For the primary analysis, all randomized participants were assigned to their randomization group""</p>","Low risk","<p>Data was available for most randomized participants.</p>","Low risk","<p>The definition is clearly stated.</p>","Low risk","<p>Data analysis was planned before randomization and performed accordance with prespecified analysis plan.&nbsp;</p>","Low risk","<p>No concerns about the risk of bias.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD016211/full","10.1002/14651858.CD016211","2::2","CD016211_data","significance_only",TRUE,TRUE,FALSE,-0.435092759704064,-0.00405764878410204,-0.601365776286879,-0.268819743121249,-0.00974038569362614,0.00162508812542207,FALSE,FALSE
1,2,"Maternal sepsis: subgroup analysis (polypharmacy vs monopharmacy)","Monopharmacy",2,"SUBGROUP_AND_OVERALL","Subramaniam 2021",2021,0,0.908504685823564,0,0,3,253,0,0,2,125,0,0.825380764163373,0.832843,0.741107,0.12544,4.378499,NA,"Low risk","<p>The sequential randomization assignments were computer generated using permuted block sizes of 3, 6, and 9, and were stratified by site.&nbsp;</p>","Low risk","<p>Only the investigational pharmacist, responsible for packaging the drug allotments, and the data-coordinating center were aware of treatment assignments. All analyses used the intention-to-treat principle.</p>","Low risk","<p>Medical records, postpartum visits or phone call and any readmission.</p>","Low risk","<p>Medical records, postpartum visits or phone call and any readmission.</p>","Low risk","<p>NCT03248297.</p>","Low risk","<p>No concerns about the risk of bias.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD016211/full","10.1002/14651858.CD016211","2::2","CD016211_data","significance_only",TRUE,TRUE,FALSE,-0.435092759704064,-0.00405764878410204,-0.601365776286879,-0.268819743121249,-0.00974038569362614,0.00162508812542207,FALSE,FALSE
1,2,"Maternal sepsis: subgroup analysis (polypharmacy vs monopharmacy)","Monopharmacy",2,"SUBGROUP_AND_OVERALL","Tita 2023",2023,0,0,0,0,219,14558,0,0,339,14662,0,0,92.70438,0.650633,0.549814,0.769938,NA,"Low risk","<p>&nbsp;""Trial packs of azithromycin and identical placebo were numbered sequentially with the use of a compyter algorithm, which used a predetermined 1:1 randomization schedule for azithromycin and placebo, stratified according to site, and a permuted-block randomization with vaaried block sizes."" There was no clear differences between the intervention group and the control group.&nbsp;</p>","Low risk","<p>""Each dose consisted of four pills of 500mg of azithromycin or placebo and were labeled with a unique package identifier. Clinicians, research staff members, and patients were unaware of trial-group assignments."""" The primary analyses were performed in the intention-to treat population.""</p>","Low risk","<p>14589 (99.4%) of 14687 participants at the intervention group and 14687 (99.4%) of 14782 at the control group had side effects data.</p>","Low risk","<p>Staff members were blinded.</p>","Low risk","<p>They planned analyses methods before unblinded outcome data were available for analyses.&nbsp;</p>","Low risk","<p>No concerns about the risk of bias.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD016211/full","10.1002/14651858.CD016211","2::2","CD016211_data","significance_only",TRUE,TRUE,FALSE,-0.435092759704064,-0.00405764878410204,-0.601365776286879,-0.268819743121249,-0.00974038569362614,0.00162508812542207,FALSE,FALSE
